Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	ORGANOVO HOLDINGS, INC.
Entity Central Index Key	0001497253
Document Type	10-Q
Document Period End Date	Sep. 30, 2012
Amendment Flag	false
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	46,969,141

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2012	Dec. 31, 2011
Current Assets
Cash and cash equivalents	$ 7,675,918	$ 339,607
Grants receivable	95,477
Inventory	312,182	291,881
Deferred financing costs		318,843
Prepaid expenses and other current assets	144,515	79,874
Total current assets	8,228,092	1,030,205
Fixed Assets - Net	605,920	278,208
Restricted cash	88,321
Other Assets	120,890	100,419
Total assets	9,043,223	1,408,832
Current Liabilities
Accounts payable	61,347	657,560
Accrued expenses	830,033	437,837
Deferred revenue	75,000	152,500
Capital lease obligation, current portion	9,845
Accrued interest payable		24,018
Convertible notes payable, current portion		703,833
Total current liabilities	976,225	1,975,748
Capital lease obligation, net current portion	19,712
Warrant liabilities	35,471,527	1,266,869
Total liabilities	34,467,464	3,242,617
Commitments and contingencies (Note 5)
Stockholders' Deficit
Common stock, $0.001 par value; 150,000,000 shares authorized, 46,969,141 and 22,445,254 issued and outstanding at September 30, 2012 and December 31, 2011, respectively	46,969	22,445
Additional paid-in capital	13,208,039	4,835,326
Deficit accumulated during the development stage	(40,679,249)	(6,691,556)
Total stockholders' deficit	(27,424,241)	(1,833,785)
Total Liabilities and Stockholders' Deficit	$ 9,043,223	$ 1,408,832

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Condensed Consolidated Balance Sheets [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	46,969,141	46,969,141
Common stock, shares outstanding	22,445,254	22,445,254

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References+ Details

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		65 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Revenues
Product				$ 100,000	$ 223,500
Collaborations	373,761	231,974	752,736	449,213	1,515,824
Grants	95,477		95,477	56,925	759,589
Total Revenues	469,238	231,974	848,213	606,138	2,498,913
Cost of product revenue				50,584	133,607
Selling, general, and administrative expenses	2,981,481	550,157	4,939,403	1,129,597	7,605,440
Research and development expenses	1,105,456	304,251	2,305,311	1,013,981	5,503,699
Loss from Operations	(3,617,699)	(622,434)	(6,396,501)	(1,588,024)	(10,743,833)
Other Income (Expense)
Fair value of warrant liabilities in excess of proceeds received			(19,019,422)		(19,019,422)
Change in fair value of warrant liabilities	42,252,357		(5,190,637)		(5,197,206)
Financing transaction costs in excess of proceeds received			(2,129,500)		(2,129,500)
Loss on disposal of fixed assets	(158,366)		(158,366)		(158,366)
Interest expense	(203)	(182,320)	(1,087,656)	(294,245)	(3,406,098)
Interest income	1,358		3,342		5,348
Other income (expense)	596	(488)	(8,953)	(2,038)	(30,172)
Total Other Income (Expense)	42,095,742	(182,808)	(27,591,192)	(296,283)	(29,935,416)
Net Income (Loss)	$ 38,478,043	$ (805,242)	$ (33,987,693)	$ (1,884,307)	$ (40,679,249)
Net income (loss) per common share - basic	$ 0.87	$ (0.07)	$ (0.86)	$ (0.16)
Net income (loss) per common share - diluted	$ 0.69	$ (0.07)	$ (0.86)	$ (0.16)
Weighted average shares used in computing net income (loss) per common share - basic	44,099,554	12,262,691	39,349,681	11,537,879
Weighted average shares used in computing net income (loss) per common share - diluted	55,849,360	12,262,691	39,349,681	11,537,879

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) (USD $)	Total	Common Stock	Additional Paid-In Capital	Deficit Accumulated During The Development Stage
Beginning balance at Dec. 31, 2007
Issuance of Common stock	1,729,532
Issuance of Common stock to founders, shares		1,729,532
Issuance of Common stock to founders		$ 1,730	$ (1,730)
Issuance of restricted Common stock, shares		12,627,697
Issuance of restricted Common stock		12,628	(12,628)
Stock-based compensation expense	1,742		1,742
Net Loss	(97,559)			(97,559)
Ending balance at Dec. 31, 2008	(95,817)	14,358	(12,616)	(97,559)
Ending balance, shares at Dec. 31, 2008		14,357,229
Issuance of restricted Common stock, shares		130,422
Issuance of restricted Common stock		130	(130)
Stock-based compensation expense	2,336		2,336
Net Loss	(872,041)			(872,041)
Ending balance at Dec. 31, 2009	(965,522)	14,488	(10,410)	(969,600)
Ending balance, shares at Dec. 31, 2009		14,487,651
Issuance of restricted Common stock, shares		219,369
Issuance of restricted Common stock		219	(219)
Stock-based compensation expense	3,856		3,856
Net Loss	(1,338,694)			(1,338,694)
Ending balance at Dec. 31, 2010	(2,300,360)	14,707	(6,773)	(2,308,294)
Ending balance, shares at Dec. 31, 2010		14,707,020
Issuance of Common stock through conversion of notes payable, shares		7,676,828
Issuance of Common stock through conversion of notes payable	3,489,758	7,677	3,482,081
Issuance of restricted Common stock, shares		61,406
Issuance of restricted Common stock		61	(61)
Warrants issued with convertible notes and conversion of notes	1,111,364		1,111,364
Beneficial conversion feature of convertible notes payable	239,700		239,700
Stock-based compensation expense	9,015		9,015
Net Loss	(4,383,262)			(4,383,262)
Ending balance at Dec. 31, 2011	(1,833,785)	22,445	4,835,326	(6,691,556)
Ending balance, shares at Dec. 31, 2011		22,445,254
Issuance of restricted Common stock, shares		1,380,000
Issuance of restricted Common stock		1,380	(1,380)
Issuance of common stock in connection with the merger, shares		6,000,000
Issuance of Common stock in connection with the merger		6,000	(6,000)
Issuance of Common stock through private placements in connection with the merger, shares		13,722,600
Issuance of Common stock through private placements in connection with the merger	13,722,600	13,723	13,708,877
Costs associated with the merger	(13,722,600)		(13,722,600)
Issuance of Common stock through conversion of notes payable and accrued interest in connection with the merger, shares		1,525,387
Issuance of Common stock through conversion of notes payable and accrued interest in connection with the merger	1,525,387	1,525	1,523,862
Issuance of warrant to consultant	72,919		72,919
Issuance of Common stock from warrant exercises, shares		1,810,831
Issuance of Common stock from warrant exercises, value	1,768,476	1,811	1,766,665
Warrant liability removed due to exercise of warrants	3,728,001		3,728,001
Issuance of Comman stock from stock option exercises, shares	224,064	224,064
Issuance of Comman stock from stock option exercises	17,925	224	17,701
Restricted stock forfeitures, Shares	138,995	(138,995)
Restricted stock forfeitures, value		(139)	139
Stock-based compensation expense	1,284,529		1,284,529
Net Loss	(33,987,693)			(33,987,693)
Ending balance at Sep. 30, 2012	$ (27,424,241)	$ 46,969	$ 13,208,039	$ (40,679,249)
Ending balance, shares at Sep. 30, 2012		46,969,141

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended		65 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Cash Flows From Operating Activities
Net loss	$ (33,987,693)	$ (1,884,307)	$ (40,679,249)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred financing costs	318,843		438,296
Loss on disposal of fixed assets	158,366		158,366
Depreciation and amortization	116,828	49,929	273,156
Amortization of debt discount	896,167	97,565	2,083,735
Interest accrued on convertible notes payable	11,616	196,680	495,392
Fair value of warrant liabilities in excess of proceeds	19,019,422		19,019,422
Change in fair value of warrant liabilities	5,190,637		5,197,206
Stock-based compensation	1,284,529	2,596	1,301,478
Amortization of warrants issued for services	36,054		36,054
Warrants issued in connection with exchange agreement			527,629
Increase (decrease) in cash resulting from changes in:
Grants receivable	(95,477)	59,744	(95,477)
Inventory	(327,993)	(212,395)	(619,874)
Prepaid expenses and other assets	(53,490)	1,044	(146,496)
Accounts payable	(596,213)	374,973	61,347
Accrued expenses	392,196	260,031	830,033
Deferred revenue	(77,500)	95,075	75,000
Net cash used in operating activities	(7,713,708)	(959,065)	(11,043,982)
Cash Flows From Investing Activities
Restricted cash deposits	(88,321)		(88,321)
Purchases of fixed assets	(255,750)	(16,920)	(682,573)
Purchases of intangible assets		(65,000)	(95,000)
Net cash used in investing activities	(344,071)	(81,290)	(865,894)
Cash Flows From Financing Activities
Proceeds from issuance of convertible notes payable		1,042,500	4,630,000
Proceeds from issuance of common stock and warrants	15,491,075		15,491,075
Proceeds from exercise of stock options	17,925		17,925
Proceeds from issuance of related party notes payable		225,000	250,000
Principal payments on capital lease obligations	(4,663)		(4,663)
Repayment of related party notes payable		(250,000)	(250,000)
Repayment of convertible notes and interest payable	(110,247)		(110,247)
Deferred financing costs		(205,984)	(438,296)
Net cash provided by financing activities	15,394,090	811,516	19,585,794
Net Increase (Decrease) in Cash and Cash Equivalents	7,336,311	(228,839)	7,675,918
Cash and Cash Equivalents at Beginning of Period	339,607	285,308
Cash and Cash Equivalents at End of Period	7,675,918	56,469	7,675,918
Supplemental Disclosure of Cash Flow Information:
Interest	10,247		10,247
Income Taxes	$ 800	$ 2,400	$ 3,200

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) (USD $)	9 Months Ended	12 Months Ended	56 Months Ended
	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2011
Condensed Consolidated Statements of Cash Flows [Abstract]
Issuance restricted Common stock to certain employees, advisors and consultants		61,406,219,369	13,038,894
Warrants and related beneficial conversion feature valued		$ 823,435	$ 823,435
Warrants issued in connection with convertible notes payable		1,260,000	1,260,000
Issuance of Common stock to note holders	1,525,387	7,676,828
Convertible Notes principal balance	1,500,000	3,030,000
Accrued interest	25,387	459,758
Issued warrants in connection with the Reverse Merger and the Private Placement	32,743,000
Purchased equipment through capital lease	34,220
Transferred amount of inventory to fixed assets	307,700
Issued warrants to purchase shares of common stock for consulting services, shares	100,000
Issued warrants to purchase shares of common stock for consulting services	$ 73,000

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2012

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

1. Summary of Significant Accounting Policies



Nature of operations and basis of presentation		References in these notes to the unaudited condensed financial statements to “Organovo Holdings, Inc.,” “Organovo Holdings,” “we,” “us,” “our,” “the Company” and “our Company” refer to Organovo Holdings, Inc. and its consolidated subsidiary Organovo, Inc. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. As of September 30, 2012, the Company has devoted substantially all of its efforts to product development, raising capital, and building infrastructure. The Company has not realized significant revenues from its planned principal operations. Accordingly, the Company is considered to be in the development stage. The accompanying interim condensed financial statements have been prepared by the Company, without audit, in accordance with the instructions to Form 10-Q and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of its financial position, results of operations and cash flows in accordance with generally accepted accounting principles (“GAAP”). The balance sheet at December 31, 2011 is derived from the audited balance sheet at that date. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of financial position, results of operations and cash flows. These financial statements should be read in conjunction with the financial statements included in the Company’s Form 8-K/A for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission (the “SEC”) on May 11, 2012. Operating results for interim periods are not necessarily indicative of operating results for the Company’s 2012 fiscal year.

Merger transaction		On February 8, 2012, Organovo, Inc., a privately held Delaware corporation, merged with and into Organovo Acquisition Corp., a wholly-owned subsidiary of the Company, a publicly traded Delaware corporation, with the Organovo, Inc. surviving the merger as a wholly-owned subsidiary of the Company (the “Merger”). As a result of the Merger, the Company acquired the business of the Organovo, Inc., and will continue the existing business operations of Organovo, Inc. Simultaneously with the Merger, on February 8, 2012 (the “closing date”), all of the issued and outstanding shares of Organovo, Inc.’s common stock converted, on a 1 for 1 basis, into shares of the Company’s Common stock, par value $0.001 per share. Also, on the closing date, all of the issued and outstanding options to purchase shares of Organovo, Inc.’s common stock and other outstanding warrants to purchase Organovo, Inc.’s common stock, and all of the issued and outstanding bridge warrants to purchase shares of Organovo, Inc.’s common stock, converted, respectively, on a 1 for 1 basis, into options, warrants and new bridge warrants to purchase shares of the Company’s common stock. Immediately following the consummation of the Merger: (i) the former security holders of Organovo, Inc. common stock had an approximate 75% voting interest in the Company and the Company stockholders retained an approximate 25% voting interest, (ii) former executive management team of Organovo, Inc. remained as the only continuing executive management team for the Company, and (iii) the Company’s ongoing operations consist solely of the ongoing operations of Organovo, Inc. Based primarily on these factors, the Merger was accounted for as a reverse merger and a recapitalization in accordance with GAAP. As a result, these financial statements reflect the historical results of Organovo, Inc. prior to the Merger, and the combined results of the Company following the Merger. The par value of Organovo, Inc. common stock immediately prior to the Merger was $0.0001 per share. The par value subsequent to the Merger is $0.001 per share, and therefore the historical results of Organovo, Inc. prior to the Merger have been retroactively adjusted to affect the change in par value. In connection with three separate closings of a private placement transaction completed in connection with the Merger (the “Private Placement”), the Company received gross proceeds of approximately $5,000,000, $1,800,000 and $6,900,000 on February 8, 2012, February 29, 2012 and March 16, 2012, respectively. The Company previously received $1,500,000 from the purchase of 6% convertible notes which were automatically converted into 1,500,000 shares of common stock, plus 25,387 shares for accrued interest of $25,387 on the principal, at February 8, 2012. See Note 3.


		The cash transaction costs related to the Merger were approximately $2,129,500. Before the Merger, Organovo Holdings’ board of directors and stockholders adopted the 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan provides for the issuance of 6,553,986 shares of the Company’s Common stock to executive officers, directors, advisory board members and employees. In addition, Organovo Holdings assumed and adopted Organovo, Inc.’s 2008 Equity Incentive Plan.

Liquidity		As of September 30, 2012, the Company had an accumulated deficit of approximately $40,679,200. The Company also had negative cash flow from operations of approximately $7,713,700 during the nine months ended September 30, 2012. On February 8, 2012, the Company received gross proceeds of approximately $5,000,000 in a private placement offering in conjunction with the Merger. On February 29, 2012 and March 16, 2012, the Company completed two additional closings of its Private Placement and received total gross proceeds of approximately $8,722,000. The Company expects to cover its anticipated operating expenses over the next twelve months through cash on hand (including the funds raised during the first quarter of 2012 through the Private Placement of its securities), funds received through equity or debt financing, and funds received from grants and its collaborative agreements, and other commercial arrangements. The Company’s ability to continue its operations is dependent upon its ability to raise additional capital through equity or debt financing, and to generate capital through collaborative research agreements and other commercial arrangements. There can be no assurance that any additional financing will be available on acceptable terms or available at all. Any equity financing may result in dilution to existing stockholders and any debt financing may include restrictive covenants. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of these uncertainties.

Use of estimates		The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the financial statements include those assumed in computing the valuation of warrants and conversion features, revenue recognized under the proportional performance model, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets.

Cash and cash equivalents		The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents.

Restricted cash		As of September 30, 2012, the Company had approximately $88,300 of restricted cash deposited with a financial institution. $38,300 is held in certificates of deposit to support a letter of credit agreement related to the facility lease entered into during 2012. The additional $50,000 is held by the financial institution as a guarantee for the Company’s commercial credit cards.

Grants receivable		Grants receivable represent amounts due from the NHLBI, a division of the NIH under three research grants. The Company considers the grants receivable to be fully collectible; and accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.

Inventory		Inventories are stated at the lower of the cost or market (first-in, first out). Inventory at September 30, 2012 consisted of approximately $48,400 in finished goods, $193,800 work-in-process and $70,000 in raw materials. Inventory at December 31, 2011 consisted of approximately $235,000 in finished goods and $56,900 in raw materials. The Company provides inventory allowances based on excess or obsolete inventories determined based on anticipated use in the final product. There was no obsolete inventory reserve as of September 30, 2012 or December 31, 2011.


Deferred financing costs		As of December 31, 2011, deferred financing costs consisted of approximately $140,000 associated with the Merger transaction and approximately $179,000 associated with convertible notes as part of the private placement offering that was initiated in the fourth quarter of 2011. The deferred financing costs related to the private placement offering were amortized over the life of the convertible notes and fully amortized to expense upon conversion of the convertible notes on February 8, 2012. The deferred financing costs associated with the Merger transaction in excess of the proceeds received were expensed at the effective Merger date. As of September 30, 2012, there were no deferred financing costs.

Fixed assets and depreciation		Property and equipment are carried at cost. Expenditures that extend the life of the asset are capitalized and depreciated. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term. As of September 30, 2012, the estimated useful life of the fixed assets range between two and five years.

Impairment of long-lived assets		In accordance with authoritative guidance the Company reviews its long-lived assets, including property and equipment and other assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. To determine recoverability of its long-lived assets, the Company evaluates whether future undiscounted net cash flows will be less than the carrying amount of the assets and adjusts the carrying amount of its assets to fair value. Management has determined that no impairment of long-lived assets occurred in the period from inception through September 30, 2012.

Fair value measurement		Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:

		• Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. As of September 30, 2012 and December 31, 2011, cash and cash equivalents were comprised of cash in checking accounts. The Company used Level 3 inputs for its valuation methodology for the warrant derivative liabilities. The estimated fair values were determined using a Monte Carlo option pricing model based on various assumptions (see Note 2). The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to fair value of derivative liabilities.

		At September 30, 2012, the estimated fair values of the liabilities measured on a recurring basis are as follows: Fair Value Measurements at September 30, 2012


	Balance at September 30, 2012		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Warrant liability	$	35,471,527		—		—	$	35,471,527

The following table presents the activity for liabilities measured at estimated fair value using unobservable inputs for the nine months ended September 30, 2012:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)


	Warrant Derivative Liability
Beginning Balance at December 31, 2011	$	1,266,869
Issuances		32,742,022
Adjustments to estimated fair value		5,190,637
Warrant liability removal due to settlements		(3,728,001	)

Ending Balance at September 30, 2012	$	35,471,527



Revenue recognition		Research and Development Revenue Under Collaborative Agreements. In December 2010, the Company entered into a 12 month research contract agreement with a third party, whereby the Company was engaged to perform research and development services on a fixed-fee basis for approximately $600,000. Based on the proportional performance criteria, the Company recognized approximately $75,000 and $75,000 and $232,000 and $449,200 in revenue related to the contract during three and nine months ended September 30, 2012 and 2011, respectively. Total revenue recognized on the contract from inception through September 30, 2012 was approximately $525,000. In October 2011, the Company entered into a research contract agreement with a third party, whereby the Company will perform research and development services on a fixed-fee basis for $1,365,000. The agreement included an initial payment to the Company of approximately $239,000, with remaining payments expected to occur over a 21-month period. During the three and nine months ended September 30, 2012, the Company recorded approximately $298,800 and $677,800, respectively, in revenue related to the research contract in recognition of the proportional performance achieved by the Company. Total revenue recognized on the contract from inception through September 30, 2012 was approximately $916,800. Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of September 30, 2012 and December 31, 2011, the Company had $75,000 and $152,500 in deferred revenue related to its collaborative research programs. NIH and U.S. Treasury Grant Revenues During 2010, the U.S. Treasury awarded the Company two one-time grants totaling approximately $397,000 for investments in qualifying therapeutic discovery projects under section 48D of the Internal Revenue Code. The grants cover reimbursement for qualifying expenses incurred by the Company in 2010 and 2009. The proceeds from these grants are classified in “Revenues – Grants” for the period from inception through September 30, 2012. During 2012, 2010 and 2009, the NHLBI, a division of the NIH, awarded the Company three research grants totaling approximately $558,000. Revenues from the NIH grants are based upon internal and subcontractor costs incurred that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors and as the Company incurs internal expenses that are related to the grants. Revenue recognized under these grants for the three and nine months ended September 30, 2012 and 2011 was approximately $95,500 and $95,500 and $0 and $57,000, respectively. Total revenue recorded under these grants from inception through September 30, 2012 was approximately $363,000.

Net income (loss) per share		Net income (loss) per share is presented as both basic and diluted net income (loss) per share. Basic net income (loss) per share excludes any dilutive effects of options, shares subject to repurchase and warrants. Diluted net income (loss) per share includes the impact of potentially dilutive securities. No dilutive effect was calculated for the nine months ended September 30, 2012 or the three and nine months ended September 30, 2011 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Total common stock equivalents that were excluded from computing diluted net income (loss) per share were approximately 429,658 and 25,801,190 for the three and nine months ended September 30, 2012, respectively, and 4,494,031 for the three and nine months ended September 30, 2011.

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References+ Details

Derivative Liability

9 Months Ended

Sep. 30, 2012

Derivative Liability [Abstract]

Derivative Liability

2. Derivative Liability

During 2012, in relation to the reverse Merger and the three offerings under the Private Placement, the Company issued 21,347,182 five-year warrants to purchase the Company’s Common stock. The exercise price of the warrants is protected against down-round financing throughout the term of the warrant, as described below. The terms of the warrants issued in the first quarter of 2012 are the same as those issued in connection with the convertible notes in October and November of 2011. Pursuant to ASC 815-15 and ASC 815-40, the fair value of the warrants of approximately $32,742,000 was recorded as a derivative liability on the issuance dates.

As of December 31, 2011, the Company had a warrant liability of $1,266,869 related to 1,500,000 warrants issued with Convertible Notes in the fourth quarter of 2011.

The Company revalued all of the warrants at the end of the period, and the estimated fair value of the outstanding warrant liabilities is $35,471,527 at September 30, 2012. The change in fair value of the derivative liabilities for the three and nine months ended September 30, 2012 was a decrease of $42,252,357 and an increase of $5,190,637, respectively, and is included in other income (expense) in the 2012 statement of operations.

During the nine months ended September 30, 2012, 1,768,475 of these warrants that are classified as derivative liabilities were exercised. The warrants were revalued as of the settlement date, and the change in fair value was recognized to earnings. The Company also recognized a reduction in the warrant liability based on the fair value as of the settlement date, with a corresponding increase in additional paid-in capital.

The derivative liabilities were valued at the closing dates of the Private Placement and at March 31, June 30 and September 30 of 2012 using a Monte Carlo valuation model with the following assumptions:


	Closing dates			March 31, 2012			June 30, 2012			September 30, 2012
Closing price per share of common stock	$	N/A		$	2.47		$	3.99		$	2.05
Exercise price per share	$	1.00		$	1.00		$	1.00		$	1.00
Expected volatility		105.8%-110.5	%		103.5	%		102.9	%		102.7	%
Risk-free interest rate		0.82%-1.07	%		1.04	%		0.72	%		0.62	%
Dividend yield		—			—			—			—
Remaining expected term of underlying securities (years)		5			4.90			4.80			4.42

In addition, as of the valuation dates, management assessed the probabilities of future financings assumptions in the Monte Carlo valuation models. Management also applied a discount for lack of marketability to the valuation of the derivative liabilities based on such trading restrictions due to the shares not being registered.

If, prior to the expiration date of the warrants, the Company issues additional shares of Common Stock, as defined below, without consideration or for a consideration per share less than the exercise price of the warrants in effect immediately prior to such issue, then the exercise price shall be reduced, concurrently with such issue, to a price (calculated to the nearest cent) determined by multiplying such exercise price by a fraction, (A) the numerator of which shall be (1) the number of shares of Common stock outstanding immediately prior to such issue plus (2) the number of shares of Common stock which the aggregate consideration received or to be received by the Company for the total number of additional shares of Common stock so issued would purchase at such exercise price; and (B) the denominator of which shall be the number of shares of Common stock outstanding immediately prior to such issue plus the number of such additional shares of Common stock so issued; provided that (i) all shares of Common stock issuable upon conversion or exchange of convertible securities outstanding immediately prior to such issue shall be deemed to be outstanding, and (ii) the number of shares of Common stock deemed issuable upon conversion or exchange of such outstanding convertible securities shall be determined without giving effect to any adjustments to the conversion or exchange price or conversion or exchange rate of such convertible securities resulting from the issuance of additional shares of Common stock that is the subject of this calculation. For purposes of the warrants, “additional shares of common stock” shall mean all shares of Common stock issued by the Company after the effective date (including without limitation any shares of Common stock issuable upon conversion or exchange of any convertible securities or upon exercise of any option or warrant, on an as-converted basis), other than: (i) shares of Common stock (and/or warrants for any class of equity securities of the Company) issued or issuable upon conversion or exchange of any convertible securities or exercise of any options or warrants outstanding on the effective date; (ii) shares of Common stock issued or issuable by reason of a dividend, stock split, split-up or other distribution on shares of Common stock; (iii) shares of Common stock (or options with respect thereto) issued or issuable to employees or directors of, or consultants to, the Company or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors of the Company; (iv) any securities issued or issuable by the Company pursuant to (A) the Private Placement; or (B) the Merger; (v) securities issued pursuant to acquisitions or strategic transactions approved by a majority of disinterested directors of the Company, provided that any


		such issuance shall only be to a person which is, itself or through its subsidiaries, an operating company in a business synergistic with the business of the Company and in which the Company receives benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities and (vi) securities issued to financial institutions, institutional investors or lessors in connection with credit arrangements, equipment financings or similar transactions approved by a majority of disinterested directors of the Company, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. Upon each adjustment of the exercise price pursuant to the provisions stated above, the number of warrant shares issuable upon exercise of the warrants shall be adjusted by multiplying a number equal to the exercise price in effect immediately prior to such adjustment by the number of warrant shares issuable upon exercise of the warrant immediately prior to such adjustment and dividing the product so obtained by the adjusted exercise price.

- Definition

The entire disclosure for the entity's entire derivative instruments and hedging activities. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708773-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4E

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624181-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4H

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624258-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 25

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80748-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41635-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708775-113959

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 45

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80784-113994

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4D

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624177-113959

+ Details

Convertible Notes Payable

9 Months Ended

Sep. 30, 2012

Convertible Notes Payable [Abstract]

Convertible Notes Payable

3. Convertible Notes Payable

Convertible notes		At December 31, 2011, an unsecured $100,000 Convertible Note, with interest at 10% and a maturity date of April 2014, remained outstanding. In February 2012, at the close of the Merger, the convertible note and accrued interest in the aggregate of approximately $110,000 were repaid.

Private placement		On September 18, 2011, Organovo, Inc.’s Board of Directors authorized a private placement offering of up to 30 units of its securities at a price of $50,000 per unit for an aggregate purchase price of $1,500,000. Each unit consisted of a convertible note in the principal amount of $50,000 accruing simple interest at the rate of 6% per annum (the “Convertible Notes”), plus five-year warrants to purchase 50,000 shares of the next Qualified Round of Equity Securities, at an exercise price of $1.00 per share. The principal plus accrued interest was convertible into the Company’s common stock upon consummation of the Merger. During October and November 2011, $1,500,000 of Convertible Notes bearing interest at 6% per annum with a maturity date of March 30, 2012, and five-year warrants to purchase 1,500,000 shares of the Company’s Common stock were issued to investors under the Private Placement. The warrants are exercisable at $1.00 per share, expire in five years, and contain down-round price protection. The Convertible Notes were outstanding at December 31, 2011, and were converted into 1,525,387 units during February 2012, in connection with the Merger. The Company determined that the warrants represent a derivative instrument due to the down-round price protection, and accordingly, the Company recorded a derivative liability related to the warrants. Additionally, upon issuance of the notes during 2011, the Company recorded the discount for the beneficial conversion feature of $239,700. The debt discount associated with the warrants and beneficial conversion feature were amortized to interest expense over the life of the Convertible Notes, and fully amortized upon conversion of the Convertible Notes. The Company recorded approximately $0 and $896,200 of interest expense for the amortization of the debt discount during the three and nine months ended September 30, 2012, respectively, and approximately $1,500,000 for the period from inception through September 30, 2012. As consideration for locating investors to participate in the Private Placement, the placement agent earned a cash payment of $195,000. Additionally, upon closing of the Merger transaction, the placement agent earned five-year warrants to purchase 610,155 shares of the Company’s Common stock at $1.00 per share. These warrants contain down round protection and were classified as derivative liabilities upon issuance. See Note 2. Interest expense, including amortization of the note discounts, for the three and nine months ended September 30, 2012 and 2011 was approximately $200 and $1,087,700 and $182,300 and $294,200, respectively. Interest expense, including amortization of the note discounts, for the period from April 19, 2007 (inception) through September 30, 2012 was approximately $3,406,100.


		During 2012, concurrently with the closing of the Merger and in contemplation of the Merger, the Company completed the initial closing of the Private Placement of up to 8,000,000 units of its securities, at a price of $1.00 per unit, with the ability to increase the offering to an aggregate of up to 16,000,000 units. Each unit consisted of one share of Common Stock and a warrant to purchase one share of Common Stock. The Company completed three closings under the Private Placement during the three months ended March 31, 2012, and raised total gross proceeds of $13,722,600 and total net proceeds of $11,593,066. The Company issued 13,722,600 shares of its Common Stock and warrants to purchase 15,247,987 shares of its Common Stock (including warrants to purchase 1,525,387 shares to former holders of the bridge notes) exercisable at $1.00 to investors in the Offering. The placement agent and its selected dealers were paid total cash commissions of $1,372,260 and the placement agent was paid an expense allowance of $411,678 and was issued placement agent warrants to purchase 6,099,195 shares of the Company’s Common Stock at an exercise price of $1.00 per share. The warrants issued to the investors and the placement agent, as described above, contain down round protection, and accordingly, were classified as derivative liabilities upon issuance. On the closing date, the derivative liabilities were recorded at an estimated fair value of approximately $32,742,000. Given that the fair value of the derivative liabilities exceeded the total proceeds of the private placement of $13,722,600, no net amounts were allocated to the common stock. The amount by which the recorded liabilities exceeded the proceeds of approximately $19,019,400 was charged to other expense at the closing dates. The Company has revalued the derivative liability as of September 30, 2012, and will continue to do so on each subsequent balance sheet date until the securities to which the derivative liabilities relate are exercised or expire, with any changes in the fair value recognized through earnings in the statement of operations. See Note 2.

Registration rights agreement		The Company entered into a registration rights agreement (each, a “Registration Rights Agreement”) with the investors in the Offering. Under the terms of the Registration Rights Agreement, the Company agreed to file a registration statement covering the resale of the Common Stock underlying the Units and the Common Stock that is issuable on exercise of the Investor Warrants (but not the Common Stock that is issuable upon exercise of the warrants issued as compensation to the placement agent in connection with the Offering) within 90 days from the final closing date of the Offering (the “Filing Deadline”). The Company filed the registration statement on June 13, 2012. The registration statement became effective during July 2012. The Company agreed to use reasonable efforts to maintain the effectiveness of the registration statement through the one year anniversary from the date the registration statement was declared effective by the Securities and Exchange Commission (the “SEC”), or until Rule 144 of the 1933 Act is available to investors in the Offering with respect to all of their shares, whichever is earlier. If the Company had not met the Effectiveness Deadline, the Company would have been liable for monetary penalties equal to one-half of one percent (0.5%) of each investor’s investment in the offering at the end of every 30 day period following such Effectiveness Deadline failure until such failure was cured. No payments shall be owed with respect to any period during which all of the investor’s registrable securities may be sold by such investor under Rule 144 or pursuant to another exemption from registration.

Stockholders' Equity

9 Months Ended

Sep. 30, 2012

Stockholders' Equity [Abstract]

Stockholders' Equity

4. Stockholders’ Equity

Common stock		During February and March 2012, the Company issued 21,247,987 shares of Common stock related to the Merger. See Notes 1 and 3. During June 2012, the Company issued 137,584 shares of common stock upon exercise of 145,000 warrants. During the three months ended September 30, 2012, the Company issued 1,673,247 shares of Common stock upon exercise of 1,675,975 warrants. During August 2012, 224,064 stock options were exercised for 224,064 shares of Common stock.

Restricted stock awards		In February 2008, four founders, including the Chief Executive Officer (“CEO”) and three directors of the Company received 11,779,960 shares of restricted Common stock, 25% vesting after the first year and the remaining 75% vesting in equal quarterly portions over the following three years. From 2008 through December 31, 2011, the Company issued a total of 1,258,934 shares of restricted Common stock to various employees, advisors, and consultants of the Company. 1,086,662 of those shares were issued under the 2008 Equity Incentive Plan and the remaining 172,272 shares were issued outside the plan. 1,380,000 shares of restricted stock were issued during the nine months ended September 30, 2012.

		During the three and nine months ended September 30, 2012, the Company issued an aggregate 950,000 of restricted stock units to certain members of senior management and 230,000 restricted stock units to non-executive employees. The vesting schedule is 25% on the anniversary of the vesting start date over 4 years. During the three and nine months ended September 30, 2012, the Company issued an aggregate 200,000 restricted stock units to certain members of senior management. The vesting of these restricted stock units are performance based. As of September 30, 2012, the Company believes the financial targets will be met, and accordingly is recognizing the related stock based compensation expense over the requisite service period. During the three and nine months ended September 30, 2012, there were 80,653 and 138,995 shares, respectively, of restricted stock cancelled. There were 190,000 restricted stock units held by two employees that vested during the period. On the vesting date, 80,653 shares of Common stock were returned to the Company, at the option of the holders, to cover the tax liability related to the vesting of the restricted stock units. Upon the return of the Common stock, stock option grants, equal to the amount of Common stock returned to the Company, with immediate vesting, were granted to the individuals at the vesting date market value strike price.


		A summary of the Company’s restricted stock award activity is as follows:


	Number of Shares
Unvested at December 31, 2007		—
Granted		12,627,697
Vested		(65,211	)
Canceled / forfeited		—

Unvested at December 31, 2008		12,562,486
Granted		130,422
Vested		(5,373,004	)
Canceled / forfeited		—

Unvested at December 31, 2009		7,319,904
Granted		219,369
Vested		(3,256,191	)
Canceled / forfeited		—

Unvested at December 31, 2010		4,283,082
Granted		61,406
Vested		(3,233,193	)
Canceled / forfeited		—

Unvested at December 31, 2011		1,111,295
Granted		1,380,000
Vested		(1,485,820	)
Canceled / forfeited		(138,995	)

Unvested at September 30, 2012		866,480


		The fair value of each restricted Common stock award is recognized as stock-based expense over the vesting term of the award. The Company recorded restricted stock-based compensation expense in operating expenses for employees and non-employees of approximately $998,100 and $998,700 and $700 and $2,600 for the three and nine months ended September 30, 2012 and 2011, respectively. The Company recorded restricted stock-based compensation expense of approximately $1,013,300 for the period from April 19, 2007 (inception) through September 30, 2012. As of September 30, 2012, total unrecognized restricted stock-based compensation expense was approximately $1,354,400, which will be recognized over a weighted average period of 1.97 years.

Stock options		Under the 2008 Equity Incentive Plan, on October 12, 2011, the Company granted an officer incentive stock options to purchase 896,256 shares of Common stock at an exercise price of $0.08 per share, a quarter of which vested on the one year anniversary of employment, in May 2012, and the remaining options will vest ratably over the remaining 36 month term. During April 2012, 305,658 incentive stock options were issued, and during the three months ended September 30, 2012, a total of 1,420,903 incentive stock options were issued, under the 2012 Equity Incentive Plan, at various exercise prices, a quarter of which will vest on either the one year anniversary of employment or one year anniversary of the vesting commencement date. The remaining options will vest ratably over the remaining 36 month terms, with the exception of 80,653 of the incentive stock option grants that have immediate vesting at the grant date and 126,000 of the incentive stock option grants that vest quarterly over 3 years.

		The following table summarizes stock option activity for the nine months ended September 30, 2012:


	Options Outstanding			Weighted- Average Exercise Price
Outstanding at December 31, 2011		896,256		$	0.08
Options Granted		1,726,561		$	1.82
Options Canceled		—			—
Options Exercised		(224,064	)		0.08

Outstanding at September 30, 2012		2,398,753		$	1.33

Vested and Exercisable at September 30, 2012		82,329		$	2.10

During the three and nine months ended September 30, 2012, the Company’s Board of Directors awarded 1,420,903 and 1,726,561 options, respectively, to certain employees. There were no stocks options granted for the same periods in 2011.

The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock based compensation expense is recognized over the vesting period using the straight-line method. The fair value of employee stock options was estimated at the grant date using the following weighted average assumptions:


	Nine months ended September 30, 2012
Dividend yield		—
Volatility		91.83	%
Risk-free interest rate		0.88	%
Expected life of options		6.04 years


		The weighted average grant date fair value per share of employee stock options granted during the nine months ended September 30, 2012 was $1.40. The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Due to the Company’s limited historical data, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options.

		The total employee stock-based compensation recorded as operating expenses was approximately $243,800 and $286,400 for the three and nine months ended September 30, 2012, respectively, and $292,800 for the period from April 19, 2007 (inception) through September 30, 2012. The total unrecognized compensation cost related to unvested stock option grants as of September 30, 2012 was approximately $2,178,700, and the weighted average period over which these grants are expected to vest is 3.66 years.

Warrants		During 2011, the Company issued warrants to purchase 2,909,750 shares of its Common stock. These warrants are immediately exercisable at $1.00 per share, and have remaining terms of approximately 4.47 years. 52,500 of the warrants were exercised during nine months ended September 30, 2012 through a cashless exercise, for issuance of 42,356 shares of common stock. During the nine months ended September 30, 2012, the Company issued warrants to purchase 21,347,182 shares of its Common stock. These warrants are immediately exercisable at $1.00 per share, and have remaining terms of approximately 4.42 years. 1,768,475 of the warrants were exercised for cash proceeds of $1,768,475 during the nine months ended September 30, 2012. These warrants were derivative liabilities and were valued at the settlement date. The warrant liability was reduced to equity at the fair value on the settlement date. See Note 2. Additionally, during the three months ended September 30, 2012 the Company entered into a 6 month agreement with a consultant for services. In connection with the agreement, the Company issued 100,000 warrants to purchase common stock, at a price of $1.70, to be earned over 6 months, with a two year life. The fair value of the warrants was estimated to be approximately $73,000. These warrants were classified as equity instruments because they do not contain any anti-dilution provisions. The Black-Scholes model, using a volatility of 79.8% and risk free factor of 0.24%, was used to determine the value. The value is being amortized over the term of the agreement. During the three and nine months ended September 30, 2012, the Company recognized approximately $36,100 of expense related to these services.

		The following table summarizes warrant activity for the nine months ended September 30, 2012:


	Warrants			Weighted- Average Exercise Price
Balance at December 31, 2011		2,909,750		$	1.00
Granted		21,447,182		$	1.00
Expired / Canceled		—		$	—
Exercised		(1,820,975	)	$	1.00

Balance at September 30, 2012		22,535,957		$	1.00

Common stock reserved for

future issuance

Common stock reserved for future issuance consisted of the following at September 30, 2012:


Common stock warrants outstanding			22,535,957
Common stock options outstanding under the 2008 Plan			672,192
Common stock options outstanding under the 2012 Plan			1,726,561

Total			24,934,710

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

+ Details

Commitments and Contingencies

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies [Abstract]

Commitments and Contingencies

5. Commitments and Contingencies

Operating leases

The Company leases office and laboratory space under non-cancelable operating leases. The Company records rent expense on a straight-line basis over the life of the lease and records the excess of expense over the amounts paid as deferred rent. Deferred rent is included in accrued expenses in the condensed balance sheets.

Rent expense was approximately $129,500 and $241,600 and $31,900 and $85,700 for the three and nine months ended September 30, 2012 and 2011, respectively. Rent expense was approximately $566,300 for the period from April 19, 2007 (inception) through September 30, 2012.

The Company entered into a new facilities lease at 6275 Nancy Ridge Drive, San Diego, CA 92121. The lease was signed on February 27, 2012 with occupancy as of July 15, 2012. The base rent under the lease is approximately $38,800 per month with 3% annual escalators. The lease term is 48 months with an option for the Company to extend the lease at the end of the lease term.

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2012, are as follows:


2012	$	3,619
2013		383,346
2014		480,644
2015		476,724
2016		271,932

Total	$	1,616,265

During the three months ended September 30, 2012, the Company entered into an agreement to lease certain laboratory equipment under a non-cancelable capital lease, which is included in fixed assets as follows:


September 30, 2012
Lab equipment	$	34,220
Less accumulated depreciation		(1,711	)

Net book value	$	32,509

Depreciation expense related to the capital lease obligation was approximately $1,700, for the three and nine months ended September 30, 2012.

Future minimum capital lease payments at September 30, 2012 are as follows:


Year Ending December 31,
2012	$	2,844
2013		10,824
2014		10,824
2015		6,856
2016		—

Total minimum lease payments		31,348

Amount representing interest		(1,791	)
Present value of minimum lease payments		29,557
Less current portion		(9,845	)

Long term portion		19,712

- Definition

The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.

+ References+ Details

Concentrations

9 Months Ended

Sep. 30, 2012

Concentrations [Abstract]

Concentrations

6. Concentrations

Credit risk		Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions primarily located in San Diego. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. At times, balances may exceed federally insured limits. The Company has not experienced losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 21, 22, 24

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6442-108592

+ Details

Subsequent Event

9 Months Ended

Sep. 30, 2012

Subsequent Event [Abstract]

Subsequent Event

7. Subsequent Event		Subsequent to September 30, 2012, the Company granted an aggregate of 363,500 incentive stock options to employees and Board of Director members. The vesting is over four years for employees and three years for Board members.

		Subsequent to September 30, 2012, the Company issued 300,000 warrants to two Consultants for Services to be provided.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2012

Summary of Significant Accounting Policies [Abstract]

Nature of operations and basis of presentation

Nature of operations and basis of

presentation

References in these notes to the unaudited condensed financial statements to “Organovo Holdings, Inc.,” “Organovo Holdings,” “we,” “us,” “our,” “the Company” and “our Company” refer to Organovo Holdings, Inc. and its consolidated subsidiary Organovo, Inc.

The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.

As of September 30, 2012, the Company has devoted substantially all of its efforts to product development, raising capital, and building infrastructure. The Company has not realized significant revenues from its planned principal operations. Accordingly, the Company is considered to be in the development stage.

The accompanying interim condensed financial statements have been prepared by the Company, without audit, in accordance with the instructions to Form 10-Q and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of its financial position, results of operations and cash flows in accordance with generally accepted accounting principles (“GAAP”). The balance sheet at December 31, 2011 is derived from the audited balance sheet at that date.

In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of financial position, results of operations and cash flows. These financial statements should be read in conjunction with the financial statements included in the Company’s Form 8-K/A for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission (the “SEC”) on May 11, 2012. Operating results for interim periods are not necessarily indicative of operating results for the Company’s 2012 fiscal year.

Merger transaction

Merger transaction

On February 8, 2012, Organovo, Inc., a privately held Delaware corporation, merged with and into Organovo Acquisition Corp., a wholly-owned subsidiary of the Company, a publicly traded Delaware corporation, with the Organovo, Inc. surviving the merger as a wholly-owned subsidiary of the Company (the “Merger”). As a result of the Merger, the Company acquired the business of the Organovo, Inc., and will continue the existing business operations of Organovo, Inc.

Simultaneously with the Merger, on February 8, 2012 (the “closing date”), all of the issued and outstanding shares of Organovo, Inc.’s common stock converted, on a 1 for 1 basis, into shares of the Company’s Common stock, par value $0.001 per share. Also, on the closing date, all of the issued and outstanding options to purchase shares of Organovo, Inc.’s common stock and other outstanding warrants to purchase Organovo, Inc.’s common stock, and all of the issued and outstanding bridge warrants to purchase shares of Organovo, Inc.’s common stock, converted, respectively, on a 1 for 1 basis, into options, warrants and new bridge warrants to purchase shares of the Company’s common stock.

Immediately following the consummation of the Merger: (i) the former security holders of Organovo, Inc. common stock had an approximate 75% voting interest in the Company and the Company stockholders retained an approximate 25% voting interest, (ii) former executive management team of Organovo, Inc. remained as the only continuing executive management team for the Company, and (iii) the Company’s ongoing operations consist solely of the ongoing operations of Organovo, Inc. Based primarily on these factors, the Merger was accounted for as a reverse merger and a recapitalization in accordance with GAAP. As a result, these financial statements reflect the historical results of Organovo, Inc. prior to the Merger, and the combined results of the Company following the Merger. The par value of Organovo, Inc. common stock immediately prior to the Merger was $0.0001 per share. The par value subsequent to the Merger is $0.001 per share, and therefore the historical results of Organovo, Inc. prior to the Merger have been retroactively adjusted to affect the change in par value.

In connection with three separate closings of a private placement transaction completed in connection with the Merger (the “Private Placement”), the Company received gross proceeds of approximately $5,000,000, $1,800,000 and $6,900,000 on February 8, 2012, February 29, 2012 and March 16, 2012, respectively. The Company previously received $1,500,000 from the purchase of 6% convertible notes which were automatically converted into 1,500,000 shares of common stock, plus 25,387 shares for accrued interest of $25,387 on the principal, at February 8, 2012. See Note 3.

The cash transaction costs related to the Merger were approximately $2,129,500.

Before the Merger, Organovo Holdings’ board of directors and stockholders adopted the 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan provides for the issuance of 6,553,986 shares of the Company’s Common stock to executive officers, directors, advisory board members and employees. In addition, Organovo Holdings assumed and adopted Organovo, Inc.’s 2008 Equity Incentive Plan.

Liquidity

Liquidity

As of September 30, 2012, the Company had an accumulated deficit of approximately $40,679,200. The Company also had negative cash flow from operations of approximately $7,713,700 during the nine months ended September 30, 2012.

On February 8, 2012, the Company received gross proceeds of approximately $5,000,000 in a private placement offering in conjunction with the Merger. On February 29, 2012 and March 16, 2012, the Company completed two additional closings of its Private Placement and received total gross proceeds of approximately $8,722,000.

The Company expects to cover its anticipated operating expenses over the next twelve months through cash on hand (including the funds raised during the first quarter of 2012 through the Private Placement of its securities), funds received through equity or debt financing, and funds received from grants and its collaborative agreements, and other commercial arrangements.

The Company’s ability to continue its operations is dependent upon its ability to raise additional capital through equity or debt financing, and to generate capital through collaborative research agreements and other commercial arrangements. There can be no assurance that any additional financing will be available on acceptable terms or available at all. Any equity financing may result in dilution to existing stockholders and any debt financing may include restrictive covenants.

The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of these uncertainties.

Use of estimates

Use of estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the financial statements include those assumed in computing the valuation of warrants and conversion features, revenue recognized under the proportional performance model, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets.

Cash and cash equivalents

Cash and cash equivalents

The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents.

Restricted cash

Restricted cash

As of September 30, 2012, the Company had approximately $88,300 of restricted cash deposited with a financial institution. $38,300 is held in certificates of deposit to support a letter of credit agreement related to the facility lease entered into during 2012. The additional $50,000 is held by the financial institution as a guarantee for the Company’s commercial credit cards.

Grants receivable

Grants receivable

Grants receivable represent amounts due from the NHLBI, a division of the NIH under three research grants. The Company considers the grants receivable to be fully collectible; and accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.

Inventory

Inventory

Inventories are stated at the lower of the cost or market (first-in, first out). Inventory at September 30, 2012 consisted of approximately $48,400 in finished goods, $193,800 work-in-process and $70,000 in raw materials. Inventory at December 31, 2011 consisted of approximately $235,000 in finished goods and $56,900 in raw materials.

The Company provides inventory allowances based on excess or obsolete inventories determined based on anticipated use in the final product. There was no obsolete inventory reserve as of September 30, 2012 or December 31, 2011.

Deferred financing costs

Deferred financing costs

As of December 31, 2011, deferred financing costs consisted of approximately $140,000 associated with the Merger transaction and approximately $179,000 associated with convertible notes as part of the private placement offering that was initiated in the fourth quarter of 2011. The deferred financing costs related to the private placement offering were amortized over the life of the convertible notes and fully amortized to expense upon conversion of the convertible notes on February 8, 2012. The deferred financing costs associated with the Merger transaction in excess of the proceeds received were expensed at the effective Merger date. As of September 30, 2012, there were no deferred financing costs.

Fixed assets and depreciation

Fixed assets and depreciation

Property and equipment are carried at cost. Expenditures that extend the life of the asset are capitalized and depreciated. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term. As of September 30, 2012, the estimated useful life of the fixed assets range between two and five years.

Impairment of long-lived assets

Impairment of long-lived assets

In accordance with authoritative guidance the Company reviews its long-lived assets, including property and equipment and other assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. To determine recoverability of its long-lived assets, the Company evaluates whether future undiscounted net cash flows will be less than the carrying amount of the assets and adjusts the carrying amount of its assets to fair value. Management has determined that no impairment of long-lived assets occurred in the period from inception through September 30, 2012.

Fair value measurement

Fair value measurement

Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:

• Level 1 — Quoted prices in active markets for identical assets or liabilities.

• Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

• Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

As of September 30, 2012 and December 31, 2011, cash and cash equivalents were comprised of cash in checking accounts.

The Company used Level 3 inputs for its valuation methodology for the warrant derivative liabilities. The estimated fair values were determined using a Monte Carlo option pricing model based on various assumptions (see Note 2). The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to fair value of derivative liabilities.

Revenue recognition

Revenue recognition

Research and Development Revenue Under Collaborative Agreements.

In December 2010, the Company entered into a 12 month research contract agreement with a third party, whereby the Company was engaged to perform research and development services on a fixed-fee basis for approximately $600,000. Based on the proportional performance criteria, the Company recognized approximately $75,000 and $75,000 and $232,000 and $449,200 in revenue related to the contract during three and nine months ended September 30, 2012 and 2011, respectively. Total revenue recognized on the contract from inception through September 30, 2012 was approximately $525,000.

In October 2011, the Company entered into a research contract agreement with a third party, whereby the Company will perform research and development services on a fixed-fee basis for $1,365,000. The agreement included an initial payment to the Company of approximately $239,000, with remaining payments expected to occur over a 21-month period. During the three and nine months ended September 30, 2012, the Company recorded approximately $298,800 and $677,800, respectively, in revenue related to the research contract in recognition of the proportional performance achieved by the Company. Total revenue recognized on the contract from inception through September 30, 2012 was approximately $916,800.

Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of September 30, 2012 and December 31, 2011, the Company had $75,000 and $152,500 in deferred revenue related to its collaborative research programs.

NIH and U.S. Treasury Grant Revenues

During 2010, the U.S. Treasury awarded the Company two one-time grants totaling approximately $397,000 for investments in qualifying therapeutic discovery projects under section 48D of the Internal Revenue Code. The grants cover reimbursement for qualifying expenses incurred by the Company in 2010 and 2009. The proceeds from these grants are classified in “Revenues – Grants” for the period from inception through September 30, 2012.

During 2012, 2010 and 2009, the NHLBI, a division of the NIH, awarded the Company three research grants totaling approximately $558,000. Revenues from the NIH grants are based upon internal and subcontractor costs incurred that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors and as the Company incurs internal expenses that are related to the grants. Revenue recognized under these grants for the three and nine months ended September 30, 2012 and 2011 was approximately $95,500 and $95,500 and $0 and $57,000, respectively. Total revenue recorded under these grants from inception through September 30, 2012 was approximately $363,000.

Net income ( loss) per share

Net income (loss) per share

Net income (loss) per share is presented as both basic and diluted net income (loss) per share. Basic net income (loss) per share excludes any dilutive effects of options, shares subject to repurchase and warrants. Diluted net income (loss) per share includes the impact of potentially dilutive securities. No dilutive effect was calculated for the nine months ended September 30, 2012 or the three and nine months ended September 30, 2011 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Total common stock equivalents that were excluded from computing diluted net income (loss) per share were approximately 429,658 and 25,801,190 for the three and nine months ended September 30, 2012, respectively, and 4,494,031 for the three and nine months ended September 30, 2011.

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2012

Summary of Significant Accounting Policies [Abstract]

Estimated fair values of the liabilities measured on a recurring basis

At September 30, 2012, the estimated fair values of the liabilities measured on a recurring basis are as follows:

Fair Value Measurements at September 30, 2012


	Balance at September 30, 2012		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Warrant liability	$	35,471,527		—		—	$	35,471,527

Activity for liabilities measured at estimated fair value using unobservable inputs

The following table presents the activity for liabilities measured at estimated fair value using unobservable inputs for the nine months ended September 30, 2012:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)


	Warrant Derivative Liability
Beginning Balance at December 31, 2011	$	1,266,869
Issuances		32,742,022
Adjustments to estimated fair value		5,190,637
Warrant liability removal due to settlements		(3,728,001	)

Ending Balance at September 30, 2012	$	35,471,527

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References+ Details

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References+ Details

Derivative Liability (Tables)

9 Months Ended

Sep. 30, 2012

Derivative Liability [Abstract]

Assumptions used to value derivative liabilities at closing dates of the Private Placements


	Closing dates			March 31, 2012			June 30, 2012			September 30, 2012
Closing price per share of common stock	$	N/A		$	2.47		$	3.99		$	2.05
Exercise price per share	$	1.00		$	1.00		$	1.00		$	1.00
Expected volatility		105.8%-110.5	%		103.5	%		102.9	%		102.7	%
Risk-free interest rate		0.82%-1.07	%		1.04	%		0.72	%		0.62	%
Dividend yield		—			—			—			—
Remaining expected term of underlying securities (years)		5			4.90			4.80			4.42

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41678-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 25

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n)(2))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2012

Stockholders' Equity [Abstract]

Summary of the Company's restricted stock award activity

A summary of the Company’s restricted stock award activity is as follows:


	Number of Shares
Unvested at December 31, 2007		—
Granted		12,627,697
Vested		(65,211	)
Canceled / forfeited		—

Unvested at December 31, 2008		12,562,486
Granted		130,422
Vested		(5,373,004	)
Canceled / forfeited		—

Unvested at December 31, 2009		7,319,904
Granted		219,369
Vested		(3,256,191	)
Canceled / forfeited		—

Unvested at December 31, 2010		4,283,082
Granted		61,406
Vested		(3,233,193	)
Canceled / forfeited		—

Unvested at December 31, 2011		1,111,295
Granted		1,380,000
Vested		(1,485,820	)
Canceled / forfeited		(138,995	)

Unvested at September 30, 2012		866,480

Summary of stock option activity

The following table summarizes stock option activity for the nine months ended September 30, 2012:


	Options Outstanding			Weighted- Average Exercise Price
Outstanding at December 31, 2011		896,256		$	0.08
Options Granted		1,726,561		$	1.82
Options Canceled		—			—
Options Exercised		(224,064	)		0.08

Outstanding at September 30, 2012		2,398,753		$	1.33

Vested and Exercisable at September 30, 2012		82,329		$	2.10

Fair value of employee stock options


	Nine months ended September 30, 2012
Dividend yield		—
Volatility		91.83	%
Risk-free interest rate		0.88	%
Expected life of options		6.04 years

Summary of warrant activity

The following table summarizes warrant activity for the nine months ended September 30, 2012:


	Warrants			Weighted- Average Exercise Price
Balance at December 31, 2011		2,909,750		$	1.00
Granted		21,447,182		$	1.00
Expired / Canceled		—		$	—
Exercised		(1,820,975	)	$	1.00

Balance at September 30, 2012		22,535,957		$	1.00

Common stock reserved for future issuance

Common stock reserved for

future issuance

Common stock reserved for future issuance consisted of the following at September 30, 2012:


Common stock warrants outstanding			22,535,957
Common stock options outstanding under the 2008 Plan			672,192
Common stock options outstanding under the 2012 Plan			1,726,561

Total			24,934,710

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies [Abstract]

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2012, are as follows:


2012	$	3,619
2013		383,346
2014		480,644
2015		476,724
2016		271,932

Total	$	1,616,265

Agreement to lease certain laboratory equipment under a non-cancelable capital lease, which is included in fixed assets


September 30, 2012
Lab equipment	$	34,220
Less accumulated depreciation		(1,711	)

Net book value	$	32,509

Future minimum capital lease payments

Future minimum capital lease payments at September 30, 2012 are as follows:


Year Ending December 31,
2012	$	2,844
2013		10,824
2014		10,824
2015		6,856
2016		—

Total minimum lease payments		31,348

Amount representing interest		(1,791	)
Present value of minimum lease payments		29,557
Less current portion		(9,845	)

Long term portion		19,712

Summary of Significant Accounting Policies (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Estimated fair values of the liabilities measured on a recurring basis
Warrant liability	$ 35,471,527	$ 1,266,869
Significant Other Unobservable Inputs (Level 3) [Member]
Estimated fair values of the liabilities measured on a recurring basis
Warrant liability	35,471,527	1,266,869
Fair Value, Measurements, Recurring [Member]
Estimated fair values of the liabilities measured on a recurring basis
Warrant liability	35,471,527
Fair Value, Measurements, Recurring [Member] \| Quoted Prices in Active Markets (Level 1) [Member]
Estimated fair values of the liabilities measured on a recurring basis
Warrant liability
Fair Value, Measurements, Recurring [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Estimated fair values of the liabilities measured on a recurring basis
Warrant liability
Fair Value, Measurements, Recurring [Member] \| Significant Other Unobservable Inputs (Level 3) [Member]
Estimated fair values of the liabilities measured on a recurring basis
Warrant liability	$ 35,471,527

Summary of Significant Accounting Policies (Details 1) (USD $)	3 Months Ended	9 Months Ended	65 Months Ended
	Sep. 30, 2012	Sep. 30, 2012	Sep. 30, 2012
Activity for liabilities measured at estimated fair value using unobservable inputs
Beginning Balance at December 31, 2011		$ 1,266,869
Adjustments to estimated fair value	(42,252,357)	5,190,637	5,197,206
Warrant liability removal due to settlements		(3,728,001)
Ending Balance at September 30, 2012	35,471,527	35,471,527	35,471,527
Significant Other Unobservable Inputs (Level 3) [Member]
Activity for liabilities measured at estimated fair value using unobservable inputs
Beginning Balance at December 31, 2011		1,266,869
Issuances		32,742,022
Adjustments to estimated fair value		5,190,637
Warrant liability removal due to settlements		(3,728,001)
Ending Balance at September 30, 2012	$ 35,471,527	$ 35,471,527	$ 35,471,527

Summary of Significant Accounting Policies (Details Textual) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended	24 Months Ended	65 Months Ended				1 Months Ended	3 Months Ended	9 Months Ended	65 Months Ended		1 Months Ended	3 Months Ended		9 Months Ended		65 Months Ended	9 Months Ended				9 Months Ended	0 Months Ended	1 Months Ended		9 Months Ended	1 Months Ended		12 Months Ended	3 Months Ended		9 Months Ended		24 Months Ended	65 Months Ended
	Feb. 08, 2012	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010 Grants	Sep. 30, 2012	Feb. 07, 2012	Dec. 31, 2009	Dec. 31, 2008	Oct. 31, 2011 Research and Development Services [Member]	Sep. 30, 2012 Research and Development Services [Member]	Sep. 30, 2012 Research and Development Services [Member]	Sep. 30, 2012 Research and Development Services [Member]	Dec. 31, 2011 Research and Development Services [Member]	Dec. 31, 2010 12 month research contract agreement [Member]	Sep. 30, 2012 12 month research contract agreement [Member]	Sep. 30, 2011 12 month research contract agreement [Member]	Sep. 30, 2012 12 month research contract agreement [Member]	Sep. 30, 2011 12 month research contract agreement [Member]	Sep. 30, 2012 12 month research contract agreement [Member]	Sep. 30, 2012 Maximum [Member]	Sep. 30, 2012 Minimum [Member]	Feb. 08, 2012 Convertible Notes Payable [Member]	Dec. 31, 2011 Convertible Notes Payable [Member]	Sep. 30, 2012 2012 Equity Incentive Plan [Member]	Mar. 16, 2012 Merger transition [Member]	Feb. 29, 2012 Merger transition [Member]	Feb. 08, 2012 Merger transition [Member]	Sep. 30, 2012 Merger transition [Member] Private_Placement	Feb. 08, 2012 Outstanding Principal Assumed on Acquisition [Member]	Feb. 08, 2012 Accrued Interest Assumed on Acquisition [Member]	Dec. 31, 2010 U.S. Treasury [Member] Grants	Sep. 30, 2012 NHLBI [Member]	Sep. 30, 2011 NHLBI [Member]	Sep. 30, 2012 NHLBI [Member]	Sep. 30, 2011 NHLBI [Member]	Dec. 31, 2010 NHLBI [Member]	Sep. 30, 2012 NHLBI [Member]
Summary of significant accounting policies (Textual) [Abstract]
Number of private placement transactions																															3
Total gross proceeds of approximately				$ 8,722,000																								$ 6,900,000	$ 1,800,000	$ 5,000,000
Convertible notes, interest rate																									6.00%
Convertible notes converted into shares of common stock																																1,500,000	25,387
Issuance of common stock																											6,553,986
Maturity of highly liquid investment																							90 days
Deferred financing costs		0		0		140,000		0																		179,000
Useful life of fixed assets, range																							10 years	2 years
Term of research contract agreement with third party																	12 months
Revenue related to research contract													298,800	677,800				75,000	232,000	75,000	449,200
Total revenue recognized from inception on the contract		469,238	231,974	848,213	606,138			2,498,913							916,800							525,000
Research and development services on a fixed-fee basis												1,365,000					600,000
Initial payment to the Company from Agreement												239,000
Remaining payments expected to occur over												21 months
Revenue from grants		95,477		95,477	56,925			759,589																										397,300	95,500	95,500	0	57,000	558,000	363,500
Deferred revenue related to its collaborative research programs		75,000		75,000		152,500		75,000					75,000	75,000	75,000	152,500
Number of grants issued							2																											2
Summary of Significant Accounting Policies (Additional Textual) [Abstract]
Conversion ratio into common stock on merger	1
Other than common stock business acquisition conversion ratio	1
Common stock, par value	$ 0.001	$ 0.001		$ 0.001		$ 0.001		$ 0.001	$ 0.0001
Former security holders common stock voting interest				75.00%
Company's stockholders retained voting interest				25.00%
Proceeds from issuance of convertible notes payable	1,500,000				1,042,500			4,630,000
Accrued interest	25,387			25,387		459,758
Cash transaction costs related to the Merger approximately				2,129,500
Accumulated deficit		(27,424,241)		(27,424,241)		(1,833,785)	(2,300,360)	(27,424,241)		(965,522)	(95,817)
Cash flow from operations				(7,713,708)	(959,065)			(11,043,982)
Restricted cash		88,321		88,321				88,321
Restricted cash		38,300		38,300				38,300
Additional restricted cash		50,000		50,000				50,000
Allowance for doubtful debts		0		0				0
Inventory of finished goods		48,400		48,400		235,000		48,400
Inventory of work in process		193,800		193,800				193,800
Inventory of raw materials		70,000		70,000		56,900		70,000
Obsolete inventory reserve		0		0		0		0
Deferred financing costs		0		0		140,000		0																		179,000
Impairment of long-lived assets								0
Estimated useful life of the fixed assets				The estimated useful life of the fixed assets range between two and ten years
Outstanding common share equivalents		429,658	4,494,031	25,801,190	4,494,031
Dilutive effect		$ 0.69	$ (0.07)	$ (0.86)	$ (0.16)
Diluted net income (loss) per share			$ 0	$ 0	$ 0

Derivative Liability (Details) (USD $)	3 Months Ended	6 Months Ended	9 Months Ended
Derivative Liability (Details) (USD $)	Mar. 31, 2012	Jun. 30, 2012	Sep. 30, 2012
Assumptions used to value derivative liabilities at closing dates of the Private Placements
Closing price per share of common stock			$ 2.05
Exercise price per share			$ 1.00
Expected volatility			102.70%
Risk-free interest rate			0.62%
Dividend yield
Warrant Derivative Liability [Member]
Assumptions used to value derivative liabilities at closing dates of the Private Placements
Closing price per share of common stock	$ 2.47	$ 3.99
Exercise price per share	$ 1.00	$ 1.00	$ 1.00
Expected volatility	103.50%	102.90%
Risk-free interest rate	1.04%	0.72%
Dividend yield
Remaining expected term of underlying securities (years)	4 years 10 months 24 days	4 years 9 months 18 days	4 years 5 months 1 day
Remaining expected term of underlying securities (years), Closing Dates			5 years
Maximum [Member] \| Warrant Derivative Liability [Member]
Assumptions used to value derivative liabilities at closing dates of the Private Placements
Expected volatility			110.50%
Risk-free interest rate			1.07%
Minimum [Member] \| Warrant Derivative Liability [Member]
Assumptions used to value derivative liabilities at closing dates of the Private Placements
Expected volatility			105.80%
Risk-free interest rate			0.82%

Derivative Liability (Details Textual) (USD $)	3 Months Ended		9 Months Ended
Derivative Liability (Details Textual) (USD $)	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2012	Mar. 31, 2012
Derivative Liability (Additional Textual) [Abstract]
Warrants maturity term			5 years
Warrant [Member]
Derivative Liability (Textual) [Abstract]
Warrants Issued		1,500,000	21,347,182
Fair value of the warrant liabilities	$ 35,471,527	$ 1,266,869	$ 35,471,527	$ 32,742,000
Change in fair value of the derivative liabilities	$ (42,252,357)		$ 5,190,637
Exercised derivative liabilities			1,768,475

Convertible Notes Payable (Details Textual) (USD $)	1 Months Ended	2 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended	65 Months Ended	9 Months Ended	2 Months Ended	12 Months Ended	9 Months Ended	2 Months Ended	3 Months Ended		9 Months Ended		65 Months Ended		1 Months Ended	9 Months Ended		1 Months Ended	9 Months Ended
Convertible Notes Payable (Details Textual) (USD $)	Feb. 29, 2012 Investment	Nov. 30, 2011	Sep. 30, 2012	Mar. 31, 2012 Private_Placement	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Sep. 30, 2012	Sep. 30, 2012 Maximum [Member] Securities	Nov. 30, 2011 Warrant [Member]	Dec. 31, 2011 Warrant [Member]	Sep. 30, 2012 Warrant [Member] Common Stock [Member] Common_Stock	Nov. 30, 2011 Convertible Notes Payable [Member]	Sep. 30, 2012 Convertible Notes Payable [Member]	Sep. 30, 2011 Convertible Notes Payable [Member]	Sep. 30, 2012 Convertible Notes Payable [Member]	Sep. 30, 2011 Convertible Notes Payable [Member]	Sep. 30, 2012 Convertible Notes Payable [Member]	Sep. 18, 2011 Convertible Notes Payable [Member]	Sep. 18, 2011 Private Placement [Member]	Sep. 30, 2012 Private Placement [Member] Warrant	Sep. 30, 2012 Private Placement [Member] Common Stock [Member]	Feb. 29, 2012 Unsecured Debt [Member] Convertible Notes Payable [Member]	Sep. 30, 2012 Unsecured Debt [Member] Convertible Notes Payable [Member]	Dec. 31, 2011 Unsecured Debt [Member] Convertible Notes Payable [Member]
Convertible Notes Payable (Textual) [Abstract]
Unsecured Convertible Note, outstanding																									$ 100,000
Convertible notes, interest rate														6.00%		6.00%		6.00%	6.00%						10.00%
Unsecured Convertible Note, maturity date																								2014-04
Convertible note and accrued interest repaid																							110,000
Private placement offering, number of units of securities			8,000,000		8,000,000			8,000,000												30
Private placement offering, price per unit																				$ 50,000
Private placement offering, aggregate purchase price																				1,500,000
Each unit consisted of a convertible note in the principal amount																				50,000
Period of warrants		5 years																		5 years
Each unit consisted of a convertible note in the principal shares																				50,000
Five-year warrants to purchase shares, exercise price per share			1.00		1.00		1.00	1.00												1.00	1.00
Convertible Notes issued													1,500,000
Exercise price of warrants, per share										$ 1.00
Expiration of warrant										5 years
Amortization of debt discount			0		896,167	97,565		2,083,735						200	1,087,700	182,300	294,200	3,406,100
Issuance of notes, recorded discount for beneficial conversion feature							239,700				239,700
Payment to Private placement agent																					195,000
Additionally placement agent earned five-year warrants to purchase shares			21,347,182		21,347,182		2,909,750	21,347,182													610,155
Private placement offering, number of units of securities Issued									16,000,000
Each unit of Common Stock												1
Warrant																					1
Closings under the private placement				3
Proceeds under Private Placement, total net				11,593,066
Shares of Common Stock and warrants issued																						13,722,600
Purchase of share of its Common Stock																					15,247,987
Share issued for warrant																					1,525,387
Issued warrants to placement agent for purchase of common stock					6,099,195
Maturity date of convertible Notes issued													Mar. 30, 2012
Convertible Notes Payable (Additional Textual) [Abstract]
Five-year warrants to purchase shares		1,500,000
Notes converted	1,525,387
Interest expense for amortization of debt discount till date								1,500,000
Derivative liabilities exceeded the proceeds, amount					19,019,400
Proceeds under Private Placement, total gross				13,722,600	13,722,600
Expense allowance paid to placement agent					411,678
Total cash commissions paid to placement agent and selected dealers					1,372,260
Private placement securities per unit price					1.00
Derivative liabilities estimated at fair value			$ 32,742,000		$ 32,742,000			$ 32,742,000
Registration Rights Agreement term					90 days
Monetary penalties charge on failure of Effectiveness Deadline					0.50%
Penalty period					30 days

Stockholders' Equity (Details)	9 Months Ended	12 Months Ended				48 Months Ended
Stockholders' Equity (Details)	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2011
Summary of the Company's restricted stock award activity
Beginning balance, Unvested, Number Of Shares	1,111,295	4,283,082	7,319,904	12,562,486
Granted, Number Of Shares	1,380,000	61,406	219,369	130,422	12,627,697	1,380,000
Vested, Number Of Shares	(1,485,820)	(3,233,193)	(3,256,191)	(5,373,004)	(65,211)
Cancel / forfeited, Number Of Shares	(138,995)
Ending balance, Unvested, Number Of Shares	866,480	1,111,295	4,283,082	7,319,904	12,562,486	1,111,295

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

+ References+ Details

Stockholders' Equity (Details 1) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended
Stockholders' Equity (Details 1) (USD $)	Apr. 30, 2012	Sep. 30, 2012	Sep. 30, 2012
Summary of warrant activity
Options Outstanding, Beginning Balance			896,256
Weighted Average Exercise Price, Options Beginning Balance			$ 0.08
Granted, Options Outstanding		1,420,903	1,726,561
Options Granted, Weighted Average Exercise Price			$ 1.82
Canceled, Options Outstanding
Options Canceled, Weighted Average Exercise Price
Exercised, Options Outstanding	(305,658)	(1,420,903)	(224,064)
Options Exercised, Weighted Average Exercise Price			$ 0.08
Options Outstanding, Ending Balance		2,398,753	2,398,753
Weighted Average Exercise Price, Options Ending Balance		$ 1.33	$ 1.33
Vested and Exercisable, Options Outstanding		82,329	82,329
Vested and Exercisable, Weighted Average Exercise Price		$ 2.10	$ 2.10

Stockholders' Equity (Details 2)	9 Months Ended
Stockholders' Equity (Details 2)	Sep. 30, 2012
Fair value of employee stock options
Dividend yield
Volatility	91.83%
Risk-free interest rate	0.88%
Expected life of options	6 years 15 days

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References+ Details

Stockholders' Equity (Details 3) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended
Stockholders' Equity (Details 3) (USD $)	Apr. 30, 2012	Sep. 30, 2012	Sep. 30, 2012
Summary of warrant activity
Options Outstanding, Beginning Balance			896,256
Granted, Options Outstanding		1,420,903	1,726,561
Exercised, Options Outstanding	(305,658)	(1,420,903)	(224,064)
Weighted Average Exercise Price, Options Beginning Balance			$ 0.08
Granted, Weighted-Average Exercise Price			$ 1.82
Expired/Canceled, Weighted-Average Exercise Price
Exercised, Weighted-Average Exercise Price			$ 0.08
Options Outstanding, Ending Balance		2,398,753	2,398,753
Weighted Average Exercise Price, Options Ending Balance		$ 1.33	$ 1.33
Warrants [Member]
Summary of warrant activity
Options Outstanding, Beginning Balance			2,909,750
Granted, Options Outstanding			22,347,182
Exercised, Options Outstanding			(1,820,975)
Weighted Average Exercise Price, Options Beginning Balance			$ 1.00
Granted, Weighted-Average Exercise Price			$ 1.00
Expired/Canceled, Weighted-Average Exercise Price
Exercised, Weighted-Average Exercise Price			$ 1.00
Options Outstanding, Ending Balance		22,535,957	22,535,957
Weighted Average Exercise Price, Options Ending Balance		$ 1.00	$ 1.00

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References+ Details

- Definition

Number of share options (or share units) exercised during the current period.

+ References+ Details

Stockholders' Equity (Details 4)	Sep. 30, 2012
Common stock capital shares reserved for future issuance
Common stock reserved for future issuance	24,934,710
Warrant [Member]
Common stock capital shares reserved for future issuance
Common stock reserved for future issuance	22,535,957
Equity Incentive Plan 2008 [Member]
Common stock capital shares reserved for future issuance
Common stock reserved for future issuance	672,192
Equity Incentive Plan 2012 [Member]
Common stock capital shares reserved for future issuance
Common stock reserved for future issuance	1,726,561

Stockholders' Equity (Details Textual) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended				48 Months Ended		3 Months Ended	9 Months Ended	3 Months Ended		9 Months Ended		48 Months Ended	65 Months Ended	3 Months Ended	9 Months Ended	65 Months Ended	9 Months Ended			1 Months Ended			48 Months Ended		9 Months Ended	48 Months Ended
Stockholders' Equity (Details Textual) (USD $)	Apr. 30, 2012	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2011	Sep. 30, 2012 Agreement with Consultant for Services [Member]	Sep. 30, 2012 Restricted Stock Units (RSUs) [Member]	Sep. 30, 2012 Restricted Stock Units (RSUs) [Member]	Sep. 30, 2012 Restricted Stock [Member]	Sep. 30, 2011 Restricted Stock [Member]	Sep. 30, 2012 Restricted Stock [Member]	Sep. 30, 2011 Restricted Stock [Member]	Dec. 31, 2011 Restricted Stock [Member]	Sep. 30, 2012 Restricted Stock [Member]	Sep. 30, 2012 Stock Options [Member]	Sep. 30, 2012 Stock Options [Member]	Sep. 30, 2012 Stock Options [Member]	Sep. 30, 2012 Warrants [Member]	Jun. 30, 2012 Warrants [Member]	Mar. 31, 2012 Merger [Member]	Feb. 29, 2008 CEO and three directors [Member]	Feb. 29, 2008 CEO and three directors [Member] Restricted Stock [Member]	Oct. 12, 2011 Equity incentive plan2008 [Member]	Dec. 31, 2011 Equity incentive plan2008 [Member] Restricted Stock [Member]	Oct. 12, 2011 Equity incentive plan2008 [Member] Stock Options [Member]	Sep. 30, 2012 Equity Incentive Plan 2012 [Member]	Dec. 31, 2011 Other Plan [Member] Restricted Stock [Member]
Stockholders' Equity (Textual) [Abstract]
Common stock, shares issued		46,969,141		46,969,141		46,969,141				46,969,141														137,584	21,247,987
Warrants exercise																								145,000
Restricted common stock to founders																		1,258,934									11,779,960		1,086,662			172,272
Common stock restricted issued number of founder																										4
Issuance of Comman stock from stock option exercises, shares	305,658	1,420,903		224,064																			1,820,975								1,380,000
Remaining options vest	36 months
Stock Option Granted, Restricted portion		126,000
Stock Option Granted, Quaterly Vesting Restricted Term		3 years
Portion of restricted common stock vesting After one year																											25.00%
Portion of restricted common stock vesting over three year																											75.00%
Total employee stock-based compensation recorded as operating expenses														$ 998,100	$ 700	$ 998,700	$ 2,600		$ 1,013,300	$ 243,800	$ 286,400	$ 292,800
Unrecognized stock-based compensation expense														1,354,400		1,354,400			1,354,400
Unrecognized stock-based compensation expense recognition maximum weighted average period																1 year 11 months 19 days
Granted incentive stock options to purchase shares of Common stock																														896,256
Granted incentive stock options to purchase shares of Common stock, exercise price																												$ 0.08
Restricted stock vesting conditions																					A quarter of which will vest on the one year anniversary of employment, in May 2012, and the remaining options will vest ratably over the remaining 36 month term						25% vesting after the first year and the remaining 75% vesting in equal quarterly portions over the following three years
Stock options granted under 2008 equity incentive plan		1,420,903		1,726,561								950,000											22,347,182
Percentage of vesting schedule												25.00%
Period for vesting schedule over start date													4 years
Total unrecognized compensation cost related to unvested stock option grants, weighted average period																					3 years 7 months 28 days
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted												200,000
Common stock issued		1,673,247
Warrants exercisable price, per share		1.00		1.00		1.00				1.00													1.70
Estimated fair value of warrants																							73,000
Purchase shares of common stock for issued warrants		21,347,182		21,347,182		2,909,750				2,909,750	100,000
Stockholders' Equity (Additional Textual) [Abstract]
Total unrecognized compensation cost related to unvested stock option grants		2,178,700		2,178,700
Weighted average grant date fair value per share of employee stock options granted				$ 1.40
Restricted stock forfeitures, Shares		80,653		138,995
Warrants exercisable price, per share		1.00		1.00		1.00				1.00													1.70
Remaining terms of warrant		9 years 6 months 29 days		9 years 6 months 29 days		4 years 5 months 19 days				4 years 5 months 19 days
Number of warrant exercised						52,500				52,500
Cashless exercise for issuance of common stock		42,356		42,356
Common stock exercised warrants		1,675,975		1,675,975
Restricted stock issued				1,380,000		61,406	219,369	130,422	12,627,697	1,380,000
Exercised cash proceeds				1,768,475
Stock option granted			0		0
Price earned in a month				6 months
Life of warrants				2 years
Recognized expenses of warrants		$ 36,100		$ 36,100

Commitments and Contingencies (Details) (USD $)	Sep. 30, 2012
Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year
2012	$ 3,619
2013	383,346
2014	480,644
2015	476,724
2016	271,932
Total	$ 1,616,265

- Definition

Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.

+ References+ Details

Commitments and Contingencies (Details 1) (Equipment [Member], USD $)	Sep. 30, 2012
Equipment [Member]
Capital Leases, Balance Sheet, Assets by Major Class, Net [Abstract]
Lab equipment	$ 34,220
Less accumulated depreciation	(1,711)
Net book value	$ 32,509

- Definition

Property, plant, or equipment held under lease agreements classified as an asset.

+ References+ Details

- Definition

The total charge for the use of long-lived depreciable assets subject to a lease meeting the criteria for capitalization.

+ References+ Details

Commitments and Contingencies (Details 2) (USD $)	Sep. 30, 2012
Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]
2012	$ 2,844
2013	10,824
2014	10,824
2015	6,856
2016
Total minimum lease payments	31,348
Amount representing interest	(1,791)
Present value of minimum lease payments	29,557
Less current portion	(9,845)
Long term portion	$ 19,712

Commitments and Contingencies (Details Textual) (USD $)	3 Months Ended		9 Months Ended		65 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Commitments and Contingencies (Textual) [Abstract]
Rent expense	$ 129,500	$ 31,900	$ 241,600	$ 85,700	$ 566,300
Base rent under the lease	$ 38,800		$ 38,800		$ 38,800
Base rent escalators	3.00%		3.00%		3.00%
Lease term with option to extend			48 months

- Definition

Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.

+ References+ Details

Subsequent Event (Details Textual)	3 Months Ended	9 Months Ended
Subsequent Event (Details Textual)	Sep. 30, 2012	Sep. 30, 2012
Subsequent Event (Textual) [Abstract]
Granted, Options Outstanding	1,420,903	1,726,561
Subsequent Event [Member]
Subsequent Event (Textual) [Abstract]
Granted, Options Outstanding		363,500
Warrants issued to consutants for services to be rendered		300,000
Number of consultant		2
Subsequent Event [Member] \| Board of Directors [Member]
Subsequent Event (Textual) [Abstract]
Incentive stock options vesting period		4 years
Subsequent Event [Member] \| Employees [Member]
Subsequent Event (Textual) [Abstract]
Incentive stock options vesting period		3 years